New study tests safer pain control for High-Risk amputation patients

NCT ID NCT07640516

Recruiting now Symptom relief Sponsor: Kasr El Aini Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study compares two drugs, dexmedetomidine and fentanyl, when added to a standard numbing medicine (bupivacaine) for nerve blocks in high-risk patients having an above-knee amputation. The goal is to see which provides better pain control during and after surgery, and whether it reduces the need for additional morphine. The trial plans to enroll 64 adults with serious heart or lung conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexmedetomidine and fentanyl (added to bupivacaine for nerve block)
What this could lead to: If it works, this could point toward a better way to manage pain during and after above-knee amputation in high-risk patients, possibly reducing the need for strong opioids like morphine.
What could go wrong: This is a small, early-stage trial with only 64 participants, so results may not apply to everyone. The study is not yet recruiting, and it focuses on pain control, not curing the underlying condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABOVE KNEE AMPUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABOVE KNEE AMPUTATION ANALGESIA ASSESSMENT FENTANYL VS DEXMEDETOMIDINE

Contacts and locations

Locations

KasrELainiH
RECRUITING

Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.